The function of HER2, in breast cancer in particular, has been subject to intense research efforts, culminating in the design of both small molecule inhibitors and monoclonal antibodies in treatment of HER2+ patients (Bublil and Yarden, 2007). This evidence concerns the gene ERBB2 and breast carcinoma.